Home LiteratureArticle Details
PMID: 7529222 Published · ppublish English Journal Article Review

Current state of interferon therapy for chronic hepatitis C.

Intervirology ·Vol. 37 ·No. 2 ·1994-00-00 ·Pages 87-100

Iino S, Hino K, Yasuda K

Abstract

The current status of interferon (IFN) therapy in chronic hepatitis C is presented, focusing on the results of studies in Japan. Depending on the IFN treatment regimen used in chronic hepatitis C, it is possible to eradicate HCV in a relatively high percentage of patients (about 40%) and to achieve a cure for chronic hepatitis C. The objective of treatment should therefore be the eradication of HCV. The efficacy of IFN in chronic hepatitis C is dependent on the dosage of IFN, duration of treatment, liver histology findings, serum HCV-RNA levels, and HCV genotype. Besides a flu-like syndrome, many adverse reactions are associated with high-dose, long-term IFN treatment. However, as a rule, full recovery or improvement follows prompt withdrawal of IFN. By modification of the IFN, it will be possible to reduce adverse reactions and to create a more effective IFN to further enhance the effect of IFN in chronic hepatitis C.

MeSH Terms
Alanine Transaminase/blood Chronic Disease Hepacivirus/genetics Hepatitis C/therapy Humans Interferons/administration & dosage,adverse effects,therapeutic use RNA, Viral/blood
Chemicals
RNA, Viral Interferons Alanine Transaminase
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Iino S
Institute of Medical Science, St. Marianna, University School of Medicine, Kawasaki, Japan.
Hino K
Yasuda K
Article Info
Journal
Intervirology
Abbr.
Intervirology
ISSN
0300-5526
Published
1994-00-00
Pages
87-100
Language
English
Region
Switzerland
NLM ID
0364265
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com